Loading…
Reported covered position: Rep. Tom Udall, Intern
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Mainstreaming Addiction Treatment Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; Reducing Barriers to Substance Use Treatment Act, All Provisions (bill has not been reintroduced yet); U.S. Department of Health and Human Services, Overdose Prevention Strategy, All Provisions; Enforcement of Pharmacies and Wholesalers Providing Buprenorphine for Opioid Use Disorder.
Mainstreaming Addiction Treatment Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
END SUD, INC. DBA END SUBSTANCE USE DISORDER via END SUD, INC. DBA END SUBSTANCE USE DISORDER
2022 · fourth_quarter · 4T
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, all provisions; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; H.R. 1647, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act, all provisions; H.R. 2617, Consolidated Appropriations Act, 2023, Section 1262, regarding eliminating additional requirements for dispensing narcotic drugs in schedule III, IV, and V for maintenance or detoxification treatment; H.R. 955, Medicaid Reentry Act, all provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; S. 586, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions; Prospective legislation relating to Medicare Advantage coverage of medication-based treatment providers; Prospective legislation relating to prior authorization requirements for medication-based treatment; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Source: Senate LDA
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Mainstreaming Addiction Treatment Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4482, Coordinating Substance Use and Homelessness Care Act of 2022, All Provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; U.S. Drug Enforcement Agency, request relating to enforcement of pharmacies and wholesalers providing buprenorphine for opioid use disorder; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs
Mainstreaming Addiction Treatment Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, all provisions; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; H.R. 1647, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act, all provisions; H.R. 2617, Consolidated Appropriations Act, 2023, Section 1262, regarding eliminating additional requirements for dispensing narcotic drugs in schedule III, IV, and V for maintenance or detoxification treatment; H.R. 955, Medicaid Reentry Act, all provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; S. 586, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions; Prospective legislation relating to Medicare Advantage coverage of medication-based treatment providers; Prospective legislation relating to prior authorization requirements for medication-based treatment; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
TREATS Act
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, all provisions; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; H.R. 1647, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act, all provisions; H.R. 2617, Consolidated Appropriations Act, 2023, Section 1262, regarding eliminating additional requirements for dispensing narcotic drugs in schedule III, IV, and V for maintenance or detoxification treatment; H.R. 955, Medicaid Reentry Act, all provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; S. 586, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions; Prospective legislation relating to Medicare Advantage coverage of medication-based treatment providers; Prospective legislation relating to prior authorization requirements for medication-based treatment; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Consolidated Appropriations Act, 2023
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, all provisions; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; H.R. 1647, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act, all provisions; H.R. 2617, Consolidated Appropriations Act, 2023, Section 1262, regarding eliminating additional requirements for dispensing narcotic drugs in schedule III, IV, and V for maintenance or detoxification treatment; H.R. 955, Medicaid Reentry Act, all provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; S. 586, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions; Prospective legislation relating to Medicare Advantage coverage of medication-based treatment providers; Prospective legislation relating to prior authorization requirements for medication-based treatment; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Restoring Hope for Mental Health and Well-Being Act of 2022
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Restoring Hope for Mental Health and Well-Being Act of 2022
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, all provisions; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; H.R. 1647, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act, all provisions; H.R. 2617, Consolidated Appropriations Act, 2023, Section 1262, regarding eliminating additional requirements for dispensing narcotic drugs in schedule III, IV, and V for maintenance or detoxification treatment; H.R. 955, Medicaid Reentry Act, all provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; S. 586, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions; Prospective legislation relating to Medicare Advantage coverage of medication-based treatment providers; Prospective legislation relating to prior authorization requirements for medication-based treatment; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Restoring Hope for Mental Health and Well-Being Act of 2022
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4482, Coordinating Substance Use and Homelessness Care Act of 2022, All Provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; U.S. Drug Enforcement Agency, request relating to enforcement of pharmacies and wholesalers providing buprenorphine for opioid use disorder; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs
Medicaid Reentry Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, all provisions; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; H.R. 1647, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act, all provisions; H.R. 2617, Consolidated Appropriations Act, 2023, Section 1262, regarding eliminating additional requirements for dispensing narcotic drugs in schedule III, IV, and V for maintenance or detoxification treatment; H.R. 955, Medicaid Reentry Act, all provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; S. 586, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions; Prospective legislation relating to Medicare Advantage coverage of medication-based treatment providers; Prospective legislation relating to prior authorization requirements for medication-based treatment; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Substance Use Prevention, Treatment, and Recovery Act
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4482, Coordinating Substance Use and Homelessness Care Act of 2022, All Provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; U.S. Drug Enforcement Agency, request relating to enforcement of pharmacies and wholesalers providing buprenorphine for opioid use disorder; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs
Substance Use Prevention, Treatment, and Recovery Act
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, all provisions; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; H.R. 1647, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act, all provisions; H.R. 2617, Consolidated Appropriations Act, 2023, Section 1262, regarding eliminating additional requirements for dispensing narcotic drugs in schedule III, IV, and V for maintenance or detoxification treatment; H.R. 955, Medicaid Reentry Act, all provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; S. 586, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions; Prospective legislation relating to Medicare Advantage coverage of medication-based treatment providers; Prospective legislation relating to prior authorization requirements for medication-based treatment; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Substance Use Prevention, Treatment, and Recovery Act
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Mainstreaming Addiction Treatment Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Mainstreaming Addiction Treatment Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, all provisions; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; H.R. 1647, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act, all provisions; H.R. 2617, Consolidated Appropriations Act, 2023, Section 1262, regarding eliminating additional requirements for dispensing narcotic drugs in schedule III, IV, and V for maintenance or detoxification treatment; H.R. 955, Medicaid Reentry Act, all provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; S. 586, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions; Prospective legislation relating to Medicare Advantage coverage of medication-based treatment providers; Prospective legislation relating to prior authorization requirements for medication-based treatment; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Mainstreaming Addiction Treatment Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; Reducing Barriers to Substance Use Treatment Act, All Provisions (bill has not been reintroduced yet); U.S. Department of Health and Human Services, Overdose Prevention Strategy, All Provisions; Enforcement of Pharmacies and Wholesalers Providing Buprenorphine for Opioid Use Disorder.
Mainstreaming Addiction Treatment Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4482, Coordinating Substance Use and Homelessness Care Act of 2022, All Provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; U.S. Drug Enforcement Agency, request relating to enforcement of pharmacies and wholesalers providing buprenorphine for opioid use disorder; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs
Coordinating Substance Use and Homelessness Care Act of 2022
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4482, Coordinating Substance Use and Homelessness Care Act of 2022, All Provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; U.S. Drug Enforcement Agency, request relating to enforcement of pharmacies and wholesalers providing buprenorphine for opioid use disorder; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs
NOPAIN Act
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, all provisions; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; H.R. 1647, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act, all provisions; H.R. 2617, Consolidated Appropriations Act, 2023, Section 1262, regarding eliminating additional requirements for dispensing narcotic drugs in schedule III, IV, and V for maintenance or detoxification treatment; H.R. 955, Medicaid Reentry Act, all provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; S. 586, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions; Prospective legislation relating to Medicare Advantage coverage of medication-based treatment providers; Prospective legislation relating to prior authorization requirements for medication-based treatment; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Mainstreaming Addiction Treatment Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Mainstreaming Addiction Treatment Act (H.R. 1384, S. 445) and policies to end substance use disorder.
Mainstreaming Addiction Treatment Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS. REDUCING BARRIERS TO SUBSTANCE TREATMENT ACT, ALL PROVISIONS (BILL NUMBER NOT YET ASSIGNED). FEDERAL POLICIES RELATED TO BUPRENORPHINE FOR THE TREATMENT OF OPIOID USE DISORDER. FEDERAL OVERDOSE PREVENTION STRATEGY. FEDERAL FUNDING FOR SUBSTANCE USE DISORDER PREVENTION AND TREATMENT. OTHER FEDERAL POLICIES RELATED TO SUBSTANCE USE DISORDER.
Mainstreaming Addiction Treatment Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS. FY22 CDC INFECTIOUS DISEASES AND THE OPIOID EPIDEMIC PROGRAM FUNDING REQUEST PROVISIONS RELATING TO SUBSTANCE USE DISORDER PREVENTION AND TREATMENT INCLUDING SYRINGE SERVICES PROGRAMS.
Mainstreaming Addiction Treatment Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, OVERDOSE PREVENTION STRATEGY, ALL PROVISIONS. U.S. DRUG ENFORCEMENT ADMINISTRATION REQUEST RELATING TO REMOVAL OF FEDERAL BUPRENORPHINE X-WAIVER. FY22 CDC INFECTIOUS DISEASES AND THE OPIOID EPIDEMIC PROGRAM FUNDING REQUEST RELATING TO SUBSTANCE USE DISORDER PREVENTION AND TREATMENT INCLUDING SYRINGE SERVICES PROGRAMS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS.
Mainstreaming Addiction Treatment Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS. U.S. DRUG ENFORCEMENT ADMINISTRATION REQUEST RELATING TO REMOVAL OF FEDERAL BUPRENORPHINE X-WAIVER. FY22 CDC INFECTIOUS DISEASES AND THE OPIOID EPIDEMIC PROGRAM FUNDING REQUEST RELATING TO SUBSTANCE USE DISORDER PREVENTION AND TREATMENT INCLUDING SYRINGE SERVICES PROGRAMS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS.
Mainstreaming Addiction Treatment Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS.
STOP Fentanyl Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, OVERDOSE PREVENTION STRATEGY, ALL PROVISIONS. U.S. DRUG ENFORCEMENT ADMINISTRATION REQUEST RELATING TO REMOVAL OF FEDERAL BUPRENORPHINE X-WAIVER. FY22 CDC INFECTIOUS DISEASES AND THE OPIOID EPIDEMIC PROGRAM FUNDING REQUEST RELATING TO SUBSTANCE USE DISORDER PREVENTION AND TREATMENT INCLUDING SYRINGE SERVICES PROGRAMS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS.
STOP Fentanyl Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS. REDUCING BARRIERS TO SUBSTANCE TREATMENT ACT, ALL PROVISIONS (BILL NUMBER NOT YET ASSIGNED). FEDERAL POLICIES RELATED TO BUPRENORPHINE FOR THE TREATMENT OF OPIOID USE DISORDER. FEDERAL OVERDOSE PREVENTION STRATEGY. FEDERAL FUNDING FOR SUBSTANCE USE DISORDER PREVENTION AND TREATMENT. OTHER FEDERAL POLICIES RELATED TO SUBSTANCE USE DISORDER.
STOP Fentanyl Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS. U.S. DRUG ENFORCEMENT ADMINISTRATION REQUEST RELATING TO REMOVAL OF FEDERAL BUPRENORPHINE X-WAIVER. FY22 CDC INFECTIOUS DISEASES AND THE OPIOID EPIDEMIC PROGRAM FUNDING REQUEST RELATING TO SUBSTANCE USE DISORDER PREVENTION AND TREATMENT INCLUDING SYRINGE SERVICES PROGRAMS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS.
STOP Stigma Act
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, OVERDOSE PREVENTION STRATEGY, ALL PROVISIONS. U.S. DRUG ENFORCEMENT ADMINISTRATION REQUEST RELATING TO REMOVAL OF FEDERAL BUPRENORPHINE X-WAIVER. FY22 CDC INFECTIOUS DISEASES AND THE OPIOID EPIDEMIC PROGRAM FUNDING REQUEST RELATING TO SUBSTANCE USE DISORDER PREVENTION AND TREATMENT INCLUDING SYRINGE SERVICES PROGRAMS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS.
STOP Stigma Act
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS. REDUCING BARRIERS TO SUBSTANCE TREATMENT ACT, ALL PROVISIONS (BILL NUMBER NOT YET ASSIGNED). FEDERAL POLICIES RELATED TO BUPRENORPHINE FOR THE TREATMENT OF OPIOID USE DISORDER. FEDERAL OVERDOSE PREVENTION STRATEGY. FEDERAL FUNDING FOR SUBSTANCE USE DISORDER PREVENTION AND TREATMENT. OTHER FEDERAL POLICIES RELATED TO SUBSTANCE USE DISORDER.
STOP Stigma Act
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS. U.S. DRUG ENFORCEMENT ADMINISTRATION REQUEST RELATING TO REMOVAL OF FEDERAL BUPRENORPHINE X-WAIVER. FY22 CDC INFECTIOUS DISEASES AND THE OPIOID EPIDEMIC PROGRAM FUNDING REQUEST RELATING TO SUBSTANCE USE DISORDER PREVENTION AND TREATMENT INCLUDING SYRINGE SERVICES PROGRAMS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS.
Medicaid Reentry Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R. 955, S.285, THE MEDICAID REENTRY ACT, ALL PROVISIONS.
STOP Fentanyl Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS. REDUCING BARRIERS TO SUBSTANCE TREATMENT ACT, ALL PROVISIONS (BILL NUMBER NOT YET ASSIGNED). FEDERAL POLICIES RELATED TO BUPRENORPHINE FOR THE TREATMENT OF OPIOID USE DISORDER. FEDERAL OVERDOSE PREVENTION STRATEGY. FEDERAL FUNDING FOR SUBSTANCE USE DISORDER PREVENTION AND TREATMENT. OTHER FEDERAL POLICIES RELATED TO SUBSTANCE USE DISORDER.
STOP Fentanyl Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS. U.S. DRUG ENFORCEMENT ADMINISTRATION REQUEST RELATING TO REMOVAL OF FEDERAL BUPRENORPHINE X-WAIVER. FY22 CDC INFECTIOUS DISEASES AND THE OPIOID EPIDEMIC PROGRAM FUNDING REQUEST RELATING TO SUBSTANCE USE DISORDER PREVENTION AND TREATMENT INCLUDING SYRINGE SERVICES PROGRAMS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS.
STOP Fentanyl Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, OVERDOSE PREVENTION STRATEGY, ALL PROVISIONS. U.S. DRUG ENFORCEMENT ADMINISTRATION REQUEST RELATING TO REMOVAL OF FEDERAL BUPRENORPHINE X-WAIVER. FY22 CDC INFECTIOUS DISEASES AND THE OPIOID EPIDEMIC PROGRAM FUNDING REQUEST RELATING TO SUBSTANCE USE DISORDER PREVENTION AND TREATMENT INCLUDING SYRINGE SERVICES PROGRAMS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS.
Medicaid Reentry Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R. 955, S.285, THE MEDICAID REENTRY ACT, ALL PROVISIONS.
Mainstreaming Addiction Treatment Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS. FY22 CDC INFECTIOUS DISEASES AND THE OPIOID EPIDEMIC PROGRAM FUNDING REQUEST PROVISIONS RELATING TO SUBSTANCE USE DISORDER PREVENTION AND TREATMENT INCLUDING SYRINGE SERVICES PROGRAMS.
Mainstreaming Addiction Treatment Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
Mainstreaming Addiction Treatment Act (H.R. 1384, S. 445) and policies to end substance use disorder.
Mainstreaming Addiction Treatment Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, OVERDOSE PREVENTION STRATEGY, ALL PROVISIONS. U.S. DRUG ENFORCEMENT ADMINISTRATION REQUEST RELATING TO REMOVAL OF FEDERAL BUPRENORPHINE X-WAIVER. FY22 CDC INFECTIOUS DISEASES AND THE OPIOID EPIDEMIC PROGRAM FUNDING REQUEST RELATING TO SUBSTANCE USE DISORDER PREVENTION AND TREATMENT INCLUDING SYRINGE SERVICES PROGRAMS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS.
Mainstreaming Addiction Treatment Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS.
Mainstreaming Addiction Treatment Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS. U.S. DRUG ENFORCEMENT ADMINISTRATION REQUEST RELATING TO REMOVAL OF FEDERAL BUPRENORPHINE X-WAIVER. FY22 CDC INFECTIOUS DISEASES AND THE OPIOID EPIDEMIC PROGRAM FUNDING REQUEST RELATING TO SUBSTANCE USE DISORDER PREVENTION AND TREATMENT INCLUDING SYRINGE SERVICES PROGRAMS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS.
Mainstreaming Addiction Treatment Act of 2021
Client: END SUD, INC. DBA END SUBSTANCE USE DISORDER · Firm: END SUD, INC. DBA END SUBSTANCE USE DISORDER
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS. REDUCING BARRIERS TO SUBSTANCE TREATMENT ACT, ALL PROVISIONS (BILL NUMBER NOT YET ASSIGNED). FEDERAL POLICIES RELATED TO BUPRENORPHINE FOR THE TREATMENT OF OPIOID USE DISORDER. FEDERAL OVERDOSE PREVENTION STRATEGY. FEDERAL FUNDING FOR SUBSTANCE USE DISORDER PREVENTION AND TREATMENT. OTHER FEDERAL POLICIES RELATED TO SUBSTANCE USE DISORDER.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
END SUD, INC. DBA END SUBSTANCE USE DISORDER via END SUD, INC. DBA END SUBSTANCE USE DISORDER
2022 · third_quarter · Q3
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs; U.S. Department of Health and Human Services, proposed rule relating to take-home methadone provisions.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE
END SUD, INC. DBA END SUBSTANCE USE DISORDER via END SUD, INC. DBA END SUBSTANCE USE DISORDER
2022 · second_quarter · Q2
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; H.R. 7666 Restoring Hope for Mental Health and Well-Being Act of 2022, section 262 regarding the amendment of the Controlled Substances Act related to maintenance and detoxification treatment; S. 4482, Coordinating Substance Use and Homelessness Care Act of 2022, All Provisions; S. 4301 Substance Use Prevention, Treatment, and Recovery Act, All Provisions; U.S. Drug Enforcement Agency, request relating to enforcement of pharmacies and wholesalers providing buprenorphine for opioid use disorder; Centers for Medicaid and Medicare Services, policy related to ensuring in-network access to treatment for opioid use disorders under Medicare advantage plans; Centers for Disease Control, Infectious Disease and Opioid Epidemic program, Fiscal Year 2023 budget, provisions related to syringe service programs
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE
END SUD, INC. DBA END SUBSTANCE USE DISORDER via END SUD, INC. DBA END SUBSTANCE USE DISORDER
2022 · first_quarter · Q1
Advocated on issues related to H.R. 1384/S. 445, Mainstreaming Addiction Treatment Act, All Provisions; Reducing Barriers to Substance Use Treatment Act, All Provisions (bill has not been reintroduced yet); U.S. Department of Health and Human Services, Overdose Prevention Strategy, All Provisions; Enforcement of Pharmacies and Wholesalers Providing Buprenorphine for Opioid Use Disorder.
Filing targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
END SUD, INC. DBA END SUBSTANCE USE DISORDER via END SUD, INC. DBA END SUBSTANCE USE DISORDER
2021 · first_quarter · RA
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS. REDUCING BARRIERS TO SUBSTANCE TREATMENT ACT, ALL PROVISIONS (BILL NUMBER NOT YET ASSIGNED). FEDERAL POLICIES RELATED TO BUPRENORPHINE FOR THE TREATMENT OF OPIOID USE DISORDER. FEDERAL OVERDOSE PREVENTION STRATEGY. FEDERAL FUNDING FOR SUBSTANCE USE DISORDER PREVENTION AND TREATMENT. OTHER FEDERAL POLICIES RELATED TO SUBSTANCE USE DISORDER.
END SUD, INC. DBA END SUBSTANCE USE DISORDER via END SUD, INC. DBA END SUBSTANCE USE DISORDER
2021 · fourth_quarter · Q4
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, OVERDOSE PREVENTION STRATEGY, ALL PROVISIONS. U.S. DRUG ENFORCEMENT ADMINISTRATION REQUEST RELATING TO REMOVAL OF FEDERAL BUPRENORPHINE X-WAIVER. FY22 CDC INFECTIOUS DISEASES AND THE OPIOID EPIDEMIC PROGRAM FUNDING REQUEST RELATING TO SUBSTANCE USE DISORDER PREVENTION AND TREATMENT INCLUDING SYRINGE SERVICES PROGRAMS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS.
H.R. 955, S.285, THE MEDICAID REENTRY ACT, ALL PROVISIONS.
Filing targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
END SUD, INC. DBA END SUBSTANCE USE DISORDER via END SUD, INC. DBA END SUBSTANCE USE DISORDER
2021 · third_quarter · Q3
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS. U.S. DRUG ENFORCEMENT ADMINISTRATION REQUEST RELATING TO REMOVAL OF FEDERAL BUPRENORPHINE X-WAIVER. FY22 CDC INFECTIOUS DISEASES AND THE OPIOID EPIDEMIC PROGRAM FUNDING REQUEST RELATING TO SUBSTANCE USE DISORDER PREVENTION AND TREATMENT INCLUDING SYRINGE SERVICES PROGRAMS. H.R.4244 STOPPING TITLES THAT OVERTLY PERPETUATE (STOP) STIGMA ACT, ALL PROVISIONS. H.R.2366, S.1457, SUPPORT, TREATMENT, AND OVERDOSE PREVENTION OF FENTANYL ACT OF 2021 OR THE STOP FENTANYL ACT OF 2021, ALL PROVISIONS.
Filing targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
END SUD, INC. DBA END SUBSTANCE USE DISORDER via END SUD, INC. DBA END SUBSTANCE USE DISORDER
2021 · second_quarter · Q2
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS. FY22 CDC INFECTIOUS DISEASES AND THE OPIOID EPIDEMIC PROGRAM FUNDING REQUEST PROVISIONS RELATING TO SUBSTANCE USE DISORDER PREVENTION AND TREATMENT INCLUDING SYRINGE SERVICES PROGRAMS.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
END SUD, INC. DBA END SUBSTANCE USE DISORDER via END SUD, INC. DBA END SUBSTANCE USE DISORDER
2021 · first_quarter · Q1
H.R.1384, S.445, THE MAINSTREAMING ADDICTION TREATMENT ACT, ALL PROVISIONS; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, PRACTICE GUIDELINES FOR THE ADMINISTRATION OF BUPRENORPHINE FOR TREATING OPIOID USE DISORDER, ALL PROVISIONS.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
END SUD, INC. DBA END SUBSTANCE USE DISORDER via END SUD, INC. DBA END SUBSTANCE USE DISORDER
2021 · first_quarter · RR
Mainstreaming Addiction Treatment Act (H.R. 1384, S. 445) and policies to end substance use disorder.